Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center.
The clinical data that have been accumulated so far suggests a significant influence of IL-2 dose and schedule on the immunobiological effects and clinical toxicities observed with this cytokine. Consequently, the series of Phase I and Phase II clinical trials conducted at the University of Texas M. D. Anderson Cancer Center in patients with advanced malignant melanoma investigating the use of IL-2 in combination with other cytokines, monoclonal antibodies, or ex vivo activated effector cells have used a common dose and schedule of IL-2 administration for which abundant immunobiological information already exists. This approach allows cross-trial comparison of experience with toxicities, immunobiological observations and clinical activity by a group of investigators within a single institution, and more rapid and valid evolution towards combination biological therapy, which preclinical data suggest will have greater activity than single agent therapy.
Parkinson
D R
DR
Division of Medicine, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Talpaz
M
M
Lee
K H
KH
Legha
S
S
Markowitz
A B
AB
Itoh
K
K
Balch
C M
CM
Murray
J L
JL
Zukiwski
A A
AA
Benjamin
R S
RS
D001685:Biological Factors / Q000008:administration & dosage; D016207:Cytokines; D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D008545:Melanoma / Q000556:secondary / Q000628:therapy*
D001685:Biological Factors; D016207:Cytokines; D007376:Interleukin-2